Traded Jul 27 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Traded Jun 26, 2026 · Filed Jul 1, 2026
Roivant Sciences's Reporting person sold $10.2M of Roivant Sciences shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$10,202,559
Shares × reported transaction price
37 days after results of May 20, 2026, 41 days before results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.0% | −0.1% | +3.1% |
| 30 days | −3.2% | +0.2% | −3.4% |
| 90 days | +4.2% | +2.5% | +1.7% |
Past results only. Not a forecast.
Traded Jul 27 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Eric Venker (President & Immunovant CEO) sold ~$6.99M of Roivant Sciences
Automatic saleTraded Jul 27 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.